Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - November 2012


Pharma Integrates 2012

28 Nov 2012 - 29 Nov 2012 - London, UK



Bookmark and Share


This is the central question that Pharma Integrates 2012 (PI2012) will tackle. PI2012 is the exclusive retreat for the bio/pharmaceutical procurement and outsourcing elite, bringing together forward thinking and influential leaders from big, emerging and generic pharma alongside leading Contract Research and Manufacturing organisations.

Participants will examine, discuss and debate:

· How to improve R&D Productivity, reduce costs and tap the potential of the emerging economies through improved collaboration

· How to choose the right external partner in an era of consolidation

· When and why should big pharma and generics’ partner

· What are the barriers to open innovation

· And much more…

Attendance will provide participants with a unique opportunity to engage in truly open, interactive and thought provoking discussion, in a prestigious Central London setting away from the day to day business pressures.

For more information on who is attending, presenting and supporting Pharma Integrates 2012, click here. Alternatively please email Christopher Watt or Samuel Thangiah, call +44 (0) 1883 332 607/676




Further information
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!